PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Clostridioides difficile (Vancomycin hydrochloride - Clostridioides difficile)
Records returned : 3 (on 07 Nov 2024 at 09:23:00). Return to search results for ' Clostridioides difficile '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
05.01.07
11.03.01
Green
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. The APC notes that although current NICE guidelines recommend vancomycin first line for treatment of C diff, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
05.01.07
Green
Formulations :
- Oral suspension
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation.
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. For any patient requiring a liquid preparation, fidaxomicin granules should be prescribed. The APC notes that although current NICE guidelines recommend vancomycin first line, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Important
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective. Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients